• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肾性骨营养不良中甲状旁腺激素、1,25-二羟维生素D3及生化指标的变化]

[Changes of PTH, 1,25(OH)2D3 and biochemistry in renal osteodystrophy].

作者信息

Jia J K, Lou D X, Zhu P

机构信息

Renal Unit, Second Hospital, Zhejang Medical University, Hangzhou.

出版信息

Zhonghua Nei Ke Za Zhi. 1994 Jan;33(1):33-6.

PMID:8045186
Abstract

The changes of plasma PTH, 1,25(OH)2D3, serum calcium, phosphorus and AKP were observed in 55 uremic patients with renal osteodystrophy. The results showed that: In all types of renal osteodystrophy, plasma PTH were markedly higher than normal (P < 0.001), while plasma 1,25(OH)2D3 and serum calcium were lower than normal (P < 0.001). In low bone-turnover uremic osteodystrophy (LTO), plasma phosphorus was markedly lower than that of high bone-turnover uremic osteodystrophy (HTO) and mixed uremic osteodystrophy (MO) (P < 0.05), and plasma 1,25(OH)2D3 was significantly lower than that of HTO (P < 0.05). In HTO and MO, serum phosphorus was much higher than normal (P < 0.001). Plasma PTH had a negative linear correlation with plasma 1,25(OH)2D3 (P < 0.05), a positive linear correlation with serum AKP (P < 0.05), but no linear correlation with the duration of hemodialysis, serum calcium, serum aluminum and bone aluminum content. Plasma 1,25(OH)2D3 had no linear correlation with the duration of hemodialysis, serum phosphorus, serum aluminum and bone aluminum content. There was no significant difference in the plasma PTH, 1,25(OH)2D3 and serum AKP between the bone aluminum stain positive and negative groups.

摘要

观察55例患有肾性骨营养不良的尿毒症患者血浆甲状旁腺激素(PTH)、1,25-二羟维生素D3[1,25(OH)2D3]、血清钙、磷及碱性磷酸酶(AKP)的变化。结果显示:在所有类型的肾性骨营养不良中,血浆PTH均显著高于正常(P<0.001),而血浆1,25(OH)2D3和血清钙低于正常(P<0.001)。在低骨转换型尿毒症骨营养不良(LTO)中,血浆磷显著低于高骨转换型尿毒症骨营养不良(HTO)和混合型尿毒症骨营养不良(MO)(P<0.05),且血浆1,25(OH)2D3显著低于HTO(P<0.05)。在HTO和MO中,血清磷远高于正常(P<0.001)。血浆PTH与血浆1,25(OH)2D3呈负线性相关(P<0.05),与血清AKP呈正线性相关(P<0.05),但与血液透析时间、血清钙、血清铝及骨铝含量无线性相关。血浆1,25(OH)2D3与血液透析时间、血清磷、血清铝及骨铝含量无线性相关。骨铝染色阳性组与阴性组之间的血浆PTH、1,25(OH)2D3及血清AKP无显著差异。

相似文献

1
[Changes of PTH, 1,25(OH)2D3 and biochemistry in renal osteodystrophy].[肾性骨营养不良中甲状旁腺激素、1,25-二羟维生素D3及生化指标的变化]
Zhonghua Nei Ke Za Zhi. 1994 Jan;33(1):33-6.
2
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
3
Zinc nutritional status modifies renal osteodystrophy in uremic rats.锌营养状况会改变尿毒症大鼠的肾性骨营养不良。
Clin Nephrol. 2001 Dec;56(6):445-58.
4
[Aluminum in renal osteodystrophy].[肾性骨营养不良中的铝]
Zhonghua Nei Ke Za Zhi. 1993 Mar;32(3):176-8.
5
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.静脉注射1,25 - 二羟胆钙化醇对尿毒症患者继发性甲状旁腺功能亢进有显著抑制作用。
J Clin Invest. 1984 Dec;74(6):2136-43. doi: 10.1172/JCI111639.
6
Serum ionized calcium, as well as phosphorus and parathyroid hormone, is associated with the plasma 1,25-dihydroxyvitamin D3 concentration in normal postmenopausal women.在正常绝经后女性中,血清离子钙以及磷和甲状旁腺激素与血浆1,25 - 二羟维生素D3浓度相关。
J Bone Miner Res. 1991 May;6(5):461-8. doi: 10.1002/jbmr.5650060506.
7
[Pathological analysis of renal osteodystrophy in 194 cases].194例肾性骨营养不良的病理分析
Zhonghua Bing Li Xue Za Zhi. 1991 Dec;20(4):280-3.
8
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病(未透析)患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.
9
A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.一种1,25-(OH)2D3的新类似物,19-去甲-1,25-(OH)2D2,可抑制尿毒症大鼠的血清甲状旁腺激素(PTH)和甲状旁腺生长,而不会提高肠道维生素D受体含量。
Am J Kidney Dis. 1997 Jul;30(1):105-12. doi: 10.1016/s0272-6386(97)90571-0.
10
Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.单独或联合使用24,25-二羟维生素D3和1,25-二羟维生素D3治疗血液透析骨病。
Miner Electrolyte Metab. 1985;11(6):358-68.